BMC rheumatology · 2026
Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sudo Masanori, Takamura Sayuri, Abe Asami, Ishikawa Hajime, Kobayashi Daisuke, Nakazono Kiyoshi, Murasawa Akira, Yamamoto Suguru, Ito Satoshi
Аннотация
BACKGROUND: To describe 52-week longitudinal clinical outcomes after escalation of subcutaneous tocilizumab (TCZ-SC) from every 2 weeks (Q2W) to once weekly (Q1W) in rheumatoid arthritis (RA) patients with inadequate clinical control during Q2W dosing, and contextualize findings using a TCZ-SC Q2W continuation cohort.
METHODS: This single-center retrospective observational study included 58 patients with RA who escalated from TCZ-SC Q2W to Q1W. The primary outcome was the overall longitudinal change in the Clinical Disease Activity Index (CDAI) through week 52, assessed using a complete-case Friedman test. Linear mixed-effects models using all available observations were fitted as sensitivity analyses. Secondary analyses included the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR), matrix metalloproteinase-3 (MMP-3), laboratory safety and renal outcomes, re-adjudicated difficult-to-treat (D2T) RA status, follow-up disposition, individual-level concomitant treatment intensification, and a Q2W continuation contextual comparison.
RESULTS: The median CDAI decreased from 16.00 at Q1W escalation to 8.20 at week 52 (complete-case Friedman test, n = 42, P < 0.001). In mixed-effects sensitivity analyses, model-estimated week-52 changes were - 5.89 points for CDAI (95% CI, - 8.15 to - 3.63), - 1.29 points for DAS28-ESR (95% CI, - 1.63 to - 0.95), - 45.8% for MMP-3 (95% CI, - 54.9% to - 34.7%), and - 4.79 mL/min/1.73 m2 for estimated glomerular filtration rate (eGFR) (95% CI, - 7.65 to - 1.92). Five patients (8.6%) fulfilled the stricter D2T RA definition. Fifteen patients lacked week-52 CDAI data because of Q1W discontinuation or interruption (n = 13) or transfer of care (n = 2); the incomplete follow-up group had higher baseline disease activity. Seven patients had documented regular systemic treatment intensification during weeks 0-12; after excluding them, the median 12-week ΔCDAI remained - 3.00 (P < 0.001). In the exploratory 12-week comparison, the median ΔCDAI was - 2.85 in the Q1W escalation cohort and - 3.40 in the Q2W residual-activity subgroup, with no significant between-group difference (P = 0.754). No serious infections or treatment discontinuations due to adverse events were documented.
CONCLUSIONS: Disease activity decreased after Q1W escalation, with directionally consistent sensitivity analyses. However, the 12-week CDAI changes did not differ significantly between the Q1W escalation cohort and the Q2W residual-activity subgroup. These descriptive findings do not establish an incremental or causal benefit of Q1W escalation.
METHODS: This single-center retrospective observational study included 58 patients with RA who escalated from TCZ-SC Q2W to Q1W. The primary outcome was the overall longitudinal change in the Clinical Disease Activity Index (CDAI) through week 52, assessed using a complete-case Friedman test. Linear mixed-effects models using all available observations were fitted as sensitivity analyses. Secondary analyses included the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR), matrix metalloproteinase-3 (MMP-3), laboratory safety and renal outcomes, re-adjudicated difficult-to-treat (D2T) RA status, follow-up disposition, individual-level concomitant treatment intensification, and a Q2W continuation contextual comparison.
RESULTS: The median CDAI decreased from 16.00 at Q1W escalation to 8.20 at week 52 (complete-case Friedman test, n = 42, P < 0.001). In mixed-effects sensitivity analyses, model-estimated week-52 changes were - 5.89 points for CDAI (95% CI, - 8.15 to - 3.63), - 1.29 points for DAS28-ESR (95% CI, - 1.63 to - 0.95), - 45.8% for MMP-3 (95% CI, - 54.9% to - 34.7%), and - 4.79 mL/min/1.73 m2 for estimated glomerular filtration rate (eGFR) (95% CI, - 7.65 to - 1.92). Five patients (8.6%) fulfilled the stricter D2T RA definition. Fifteen patients lacked week-52 CDAI data because of Q1W discontinuation or interruption (n = 13) or transfer of care (n = 2); the incomplete follow-up group had higher baseline disease activity. Seven patients had documented regular systemic treatment intensification during weeks 0-12; after excluding them, the median 12-week ΔCDAI remained - 3.00 (P < 0.001). In the exploratory 12-week comparison, the median ΔCDAI was - 2.85 in the Q1W escalation cohort and - 3.40 in the Q2W residual-activity subgroup, with no significant between-group difference (P = 0.754). No serious infections or treatment discontinuations due to adverse events were documented.
CONCLUSIONS: Disease activity decreased after Q1W escalation, with directionally consistent sensitivity analyses. However, the 12-week CDAI changes did not differ significantly between the Q1W escalation cohort and the Q2W residual-activity subgroup. These descriptive findings do not establish an incremental or causal benefit of Q1W escalation.